Conducted 35 National & International clinical trials as Principal investigator & Co-investigator Phase – II, III & IV trails GCP Certified. Some of the trials have changed the medical practices and guidelines like PARADIGM HF, RELY , PARAGON , etc
Project Title : 110: A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : Empagliflozin
No. of Patient Randomized / Screened : Screen – 45 | Randomized - 19
Status : Completed
Project Title : 121: A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patient with chronic Heart Failure with reserved ejection fraction (HFrEF).
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : Empaglifozin
No. of Patient Randomized / Screened : Screen – 78 | Randomized - 48
Status : Completed
Project Title : Ultimaster: Prospective, single arm multicenter, observational Registry to further validate Safety and Efficacy of the ultimaster DES in Real world patient
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : Ultimaster Stent
No. of Patient Randomized / Screened : 30
Status : Completed
Project Title : A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : LCZ 696
No. of Patient Randomized / Screened : Screen – 31 | Randomized - 13
Status : Completed
Project Title : A multi-Center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril on Morbidity and Mortality in High Risk Patient following an Acute Myocardial Infraction.
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : LCZ 696
No. of Patient Randomized / Screened : Screen – 20 | Randomized – 20
Status : Completed
Project Title : A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : TQJ230
No. of Patient Randomized / Screened : Screen – 66 | Randomized – 35
Status : Ongoing
Project Title : A prospective, multicenter, randomized, open label, active controlled study to assess effect of Remogliflozin on biomarkers of heart failure compared to Empagliflozin in patients of type 2 diabetes mellitus with chronic heart failure (REMIT-HF)
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : Empagliflozin/ Remogliflozin
No. of Patient Randomized / Screened : Screen – 08 | Randomized – 20
Status : Completed
Project Title : Protocol number: (1245‐0202)‐ EMPACT‐MI: A streamlined, multicenter, randomized, parallel group, double blind placebo controlled,superiority trial to evaluate the effect of EMPAgliflozin on hospitalization for heart failure and mortality in patients with aCuTe myocardial infarction
Principal Investigator : Dr. Ashwani Mehta
Investigational Drug / Indication : Empagliflozin
No. of Patient Randomized / Screened : Screen – 2 | Randomized – 2
Status : Ongoing